NASDAQ:GYRE Gyre Therapeutics Q3 2026 Earnings Results & Report $4.28 -0.38 (-8.06%) As of 02:17 PM Eastern This is a fair market value price provided by Massive. Learn more. Gyre Therapeutics beat analyst expectations on both earnings and revenue in its Q3 2026 results, released November 5, 2026. The company reported EPS of $0.04 versus the -$0.15 consensus estimate, while revenue of $32.93 million topped the $28.40 million estimate by $4.53 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 5, 2026TimeAfter Market ClosesConference Call4:00 PM ET Gyre Therapeutics EPS ResultsActual EPS$0.04Consensus EPS -$0.15Beat/MissBeat by +$0.19One Year Ago EPSN/AEPS Beat Rate2 of last 8 quartersGyre Therapeutics Revenue ResultsActual Revenue$32.93 millionExpected Revenue$28.40 millionBeat/MissBeat by +$4.53 millionYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Gyre Therapeutics Q3 2026 Earnings FAQ Did Gyre Therapeutics beat earnings estimates for Q3 2026? Gyre Therapeutics (NASDAQ:GYRE) reported earnings of $0.04 per share for Q3 2026, beating the consensus estimate of -$0.15. The report was announced on Thursday, November 5, 2026. What was Gyre Therapeutics' revenue for Q3 2026? Gyre Therapeutics reported revenue of $32.93 million for Q3 2026, against a consensus estimate of $28.40 million. Gyre Therapeutics Earnings HeadlinesGyre Therapeutics (NASDAQ:GYRE) Shares Climb 14.5% After Strong EarningsNovember 8 at 1:41 AM | americanbankingnews.comGyre Therapeutics (NASDAQ:GYRE) Stock Rating Raised to "Hold" at Wall Street ZenNovember 7 at 1:13 AM | americanbankingnews.comA free stock pick, from me to youElon's paid this chip supplier since 2012. When NVIDIA tried to buy the company, he fought the deal. Without its chip, his AI satellites don't fly. Now he wants 1,000,000 of them in orbit, 100 times what's up there today, and every one pays this company a royalty. Dylan believes shares could react by December 8th.November 10 at 1:00 AM | Behind the Markets (Ad)Gyre Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 5, 2026 | marketscreener.comMGyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business UpdatesNovember 5, 2026 | globenewswire.comGyre Therapeutics (GYRE) Set to Post Earnings on FridayOctober 30, 2026 | americanbankingnews.comSee More Gyre Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Gyre Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Gyre Therapeutics and other key companies, straight to your email. Email Address About Gyre TherapeuticsGyre Therapeutics (NASDAQ:GYRE) is a biopharmaceutical company focused on developing therapies for fibrotic diseases, including pulmonary and liver fibrosis. The company’s lead development program is F351, also known as hydronidone, an investigational small-molecule therapy designed to inhibit the progression of fibrosis. F351 is being evaluated in clinical programs for idiopathic pulmonary fibrosis and liver fibrosis associated with chronic liver disease, including nonalcoholic steatohepatitis-related fibrosis. The company’s pipeline and development activities are centered primarily on diseases for which current treatment options remain limited. Gyre Therapeutics was formed through a corporate transaction involving Catalyst Biosciences and Beijing Continent Pharmaceuticals, a China-based biopharmaceutical company. The combined company has operations and development activities spanning the United States and China, with clinical research and pharmaceutical development conducted through its affiliated businesses.View Gyre Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles DraftKings Just Lost 20%—And Its Biggest Gamble Is Still AheadBarrick's Earnings Beat Could Be Overshadowed by an Even Bigger OpportunityAxon vs. Motorola: Which Public Safety Stock Has More Upside After Q3 Earnings?Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?Wall Street May Be Making a Big Mistake With monday.com StockCloudflare's 20% Sell-Off May Have Created an Opening for InvestorsMarketBeat Week in Review – 11/2 - 11/6 Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
